BiotechTube

Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma, Exercise-Induced

Conditions

Asthma, Exercise-Induced

Trial Timeline

Dec 1, 2005 → Sep 1, 2006

NCT ID
NCT00245570

About Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)

Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol) is a phase 3 stage product being developed by Organon for Asthma, Exercise-Induced. The current trial status is completed. This product is registered under clinical trial identifier NCT00245570. Target conditions include Asthma, Exercise-Induced.

What happened to similar drugs?

20 of 20 similar drugs in Asthma, Exercise-Induced were approved

Approved (20) Terminated (1) Active (0)
✅DuleraMerckApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅levalbuterol HCl + albuterol SulfateSumitomo PharmaApproved
✅arformoterol (RR formoterol) + placebo + levalbuterolSumitomo PharmaApproved
✅Racemic albuterol (R+S albuterol) + Levalbuterol (R albuterol)Sumitomo PharmaApproved
✅BenralizumabAstraZenecaApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00245570Phase 3Completed

Competing Products

20 competing products in Asthma, Exercise-Induced

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
40
DuleraMerckApproved
43
BriquilimabJasper TherapeuticsPhase 1
11
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
35
RoflumilastAstraZenecaPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
35
Regadenoson + PlaceboAstellas PharmaApproved
43
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
40
rabeprazoleEisaiPhase 3
40
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
Placebo + BrodalumabKyowa KirinPhase 2
27
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
35
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40